Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 199

1.

May P-glycoprotein status be used to stratify high-grade osteosarcoma patients? Results from the Italian/Scandinavian Sarcoma Group 1 treatment protocol.

Serra M, Pasello M, Manara MC, Scotlandi K, Ferrari S, Bertoni F, Mercuri M, Alvegard TA, Picci P, Bacci G, Smeland S.

Int J Oncol. 2006 Dec;29(6):1459-68.

PMID:
17088985
2.

Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols.

Kager L, Zoubek A, Pötschger U, Kastner U, Flege S, Kempf-Bielack B, Branscheid D, Kotz R, Salzer-Kuntschik M, Winkelmann W, Jundt G, Kabisch H, Reichardt P, Jürgens H, Gadner H, Bielack SS; Cooperative German-Austrian-Swiss Osteosarcoma Study Group..

J Clin Oncol. 2003 May 15;21(10):2011-8.

PMID:
12743156
3.

P-glycoprotein expression: critical determinant in the response to osteosarcoma chemotherapy.

Chan HS, Grogan TM, Haddad G, DeBoer G, Ling V.

J Natl Cancer Inst. 1997 Nov 19;89(22):1706-15.

PMID:
9390540
4.

P-glycoprotein expression in osteosarcoma: a basis for risk-adapted adjuvant chemotherapy.

Baldini N, Scotlandi K, Serra M, Picci P, Bacci G, Sottili S, Campanacci M.

J Orthop Res. 1999 Sep;17(5):629-32.

PMID:
10569469
5.

[Expression of MDR1 and GST-pi in osteosarcoma and soft tissue sarcoma and their correlation with chemotherapy resistance].

Wei L, Song XR, Wang XW, Li M, Z uo WS.

Zhonghua Zhong Liu Za Zhi. 2006 Jun;28(6):445-8. Chinese.

PMID:
17152492
6.

Long-term results after combined modality treatment for non-metastatic osteosarcoma.

Aparicio J, Segura A, Montalar J, Garcerá S, Oltra A, Santaballa A, Yuste A, Pastor M, Munárriz B.

Med Oncol. 1999 Dec;16(4):255-60.

PMID:
10618688
7.

Multidrug resistance and malignancy in human osteosarcoma.

Scotlandi K, Serra M, Nicoletti G, Vaccari M, Manara MC, Nini G, Landuzzi L, Colacci A, Bacci G, Bertoni F, Picci P, Campanacci M, Baldini N.

Cancer Res. 1996 May 15;56(10):2434-9.

8.

Multiple drug resistance in osteogenic sarcoma: INT0133 from the Children's Oncology Group.

Schwartz CL, Gorlick R, Teot L, Krailo M, Chen Z, Goorin A, Grier HE, Bernstein ML, Meyers P; Children's Oncology Group..

J Clin Oncol. 2007 May 20;25(15):2057-62.

PMID:
17513810
9.

Value of P-glycoprotein and clinicopathologic factors as the basis for new treatment strategies in high-grade osteosarcoma of the extremities.

Serra M, Scotlandi K, Reverter-Branchat G, Ferrari S, Manara MC, Benini S, Incaprera M, Bertoni F, Mercuri M, Briccoli A, Bacci G, Picci P.

J Clin Oncol. 2003 Feb 1;21(3):536-42.

PMID:
12560446
10.

Results of the Brazilian Osteosarcoma Treatment Group Studies III and IV: prognostic factors and impact on survival.

Petrilli AS, de Camargo B, Filho VO, Bruniera P, Brunetto AL, Jesus-Garcia R, Camargo OP, Pena W, Péricles P, Davi A, Prospero JD, Alves MT, Oliveira CR, Macedo CR, Mendes WL, Almeida MT, Borsato ML, dos Santos TM, Ortega J, Consentino E; Brazilian Osteosarcoma Treatment Group Studies III and IV..

J Clin Oncol. 2006 Mar 1;24(7):1161-8.

PMID:
16505436
11.

Scandinavian Sarcoma Group Osteosarcoma Study SSG VIII: prognostic factors for outcome and the role of replacement salvage chemotherapy for poor histological responders.

Smeland S, Müller C, Alvegard TA, Wiklund T, Wiebe T, Björk O, Stenwig AE, Willén H, Holmström T, Follerås G, Brosjö O, Kivioja A, Jonsson K, Monge O, Saeter G.

Eur J Cancer. 2003 Mar;39(4):488-94.

PMID:
12751380
12.

[P-glycoprotein expression in osteosarcoma].

Pösl M, Grahl K, Amling M, Werner M, Ritzel H, Stenzel I, Hentz M, Winkler K, Delling G.

Pathologe. 1996 Jan;17(1):50-5. German.

PMID:
8685096
14.

Telangiectatic osteosarcoma of the extremity: neoadjuvant chemotherapy in 24 cases.

Bacci G, Ferrari S, Ruggieri P, Biagini R, Fabbri N, Campanacci L, Bacchini P, Longhi A, Forni C, Bertoni F.

Acta Orthop Scand. 2001 Apr;72(2):167-72.

PMID:
11372948
16.

Prognostic significance of immunohistochemical expression of ezrin in non-metastatic high-grade osteosarcoma.

Ferrari S, Zanella L, Alberghini M, Palmerini E, Staals E, Bacchini P.

Pediatr Blood Cancer. 2008 Apr;50(4):752-6.

PMID:
17886294
17.
19.

Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome.

Baldini N, Scotlandi K, Barbanti-Bròdano G, Manara MC, Maurici D, Bacci G, Bertoni F, Picci P, Sottili S, Campanacci M, et al.

N Engl J Med. 1995 Nov 23;333(21):1380-5.

20.

Neoadjuvant chemotherapy for radioinduced osteosarcoma of the extremity: The Rizzoli experience in 20 cases.

Bacci G, Longhi A, Forni C, Fabbri N, Briccoli A, Barbieri E, Mercuri M, Balladelli A, Ferrari S, Picci P.

Int J Radiat Oncol Biol Phys. 2007 Feb 1;67(2):505-11. Epub 2006 Nov 21.

PMID:
17118571

Supplemental Content

Support Center